Investor Backing & Capital Strength:
A $30M Series B led by Andreessen Horowitz, bringing total funding to $50M, signals ample expansion capital and strong sponsor conviction. Public launch timing and subsequent scaling activity align with use of growth capital.
Market Expansion:
The company cites serving 500+ providers across all 50 states and is broadening from ABA into PT and ENT/Allergy, indicating growing geographic and specialty reach. Plans to extend into home health, long-term care, and substance use disorders further underscore an active expansion strategy.
Strategic Partnerships:
A formal partnership with Flychain announced in October 2025 reflects ecosystem traction and an expanding go-to-market footprint. Related claims about scale in ABA billing suggest influence within its initial beachhead vertical.
